FindTrial
Sign In

Rituximab Biosimilar

BIOLOGICAL7 trials

Sponsors

Huiqiang Huang, Istituto Giannina Gaslini, Merck Sharp & Dohme LLC

Conditions

Diffuse Large B-Cell LymphomaFollicular LymphomaLymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, Large B-Cell, Diffuse (DLBCL)Nephrotic Syndrome Steroid-Dependent

Phase 2

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
NCT04246359
Huiqiang HuangLymphoma, B-Cell
Start: 2020-01-15End: 2023-01-16Target: 52Updated: 2022-04-07
Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome
TerminatedNCT04402580
Istituto Giannina GasliniNephrotic Syndrome Steroid-Dependent
Start: 2019-07-01End: 2020-08-31Updated: 2020-09-14
Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.
NCT04585152
Istituto Giannina GasliniNephrotic Syndrome Steroid-Dependent
Start: 2020-10-15End: 2023-09-30Target: 160Updated: 2022-12-21
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Active, not recruitingNCT05406401
Merck Sharp & Dohme LLCLymphoma, Large B-Cell, Diffuse (DLBCL)
Start: 2022-07-14End: 2029-04-26Target: 60Updated: 2024-10-15
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingNCT06890884
Merck Sharp & Dohme LLCLymphoma, Large B-Cell, Diffuse
Start: 2025-04-11End: 2032-12-16Target: 594Updated: 2026-07-17
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingNCT07634471
Merck Sharp & Dohme LLCFollicular Lymphoma
Start: 2026-06-22End: 2035-07-23Target: 960Updated: 2026-07-10

Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingNCT06717347
Merck Sharp & Dohme LLCDiffuse Large B-Cell Lymphoma
Start: 2025-01-27End: 2032-03-29Target: 1046Updated: 2026-07-16

Related Papers

waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).
Journal of Clinical Oncology2026-05-28
Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007
Blood2025-11-03
Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study
Blood2025-11-03
Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study
Blood2025-11-03
Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study
Blood2025-11-03
waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma.
Journal of Clinical Oncology2025-05-281 citations
Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
Blood2024-11-052 citations
Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study
Blood2023-11-02
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
Journal of Clinical Oncology2023-06-011 citations
Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study
Blood2021-11-05
Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol
BMJ Open2021-11-0110 citations